Detailed Review Of Prospects For argenx SE Stock

argenx SE [ARGX] stock is trading at $376.76, up 1.35%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ARGX shares have gain 3.19% over the last week, with a monthly amount drifted -2.84%, and not seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


On 22, November 2022, argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review. In a post published today on Yahoo Finance, – Prescription Drug User Fee Act (PDUFA) target action date is March 20, 2023.

From an analyst’s perspective:

Previously, Robert W. Baird downgraded its rating to Neutral on July 29, 2022, and elevated its price target to $460. Morgan Stanley upgraded its rating to a Overweight but stick to its price target of $375 on May 03, 2022. Wells Fargo initiated its recommendation with a Overweight and recommended $390 as its price target on December 08, 2021. Piper Sandler upgraded its rating to Overweight for this stock on November 29, 2021, and upped its price target to $354. In a note dated October 29, 2021, Guggenheim upgraded an Buy rating on this stock but restated the target price of $330.

argenx SE [ARGX] stock has fluctuated between $249.50 and $403.77 over the past year. Currently, Wall Street analysts expect the stock to reach $437.20 within the next 12 months. argenx SE [NASDAQ: ARGX] shares were valued at $376.76 at the most recent close of the market. An investor can expect a potential return of 16.04% based on the average ARGX price forecast.

Analyzing the ARGX fundamentals

argenx SE [NASDAQ:ARGX] reported sales of 90.27 billion for the most recent quarter, which represents a growth of 1961.80%. In this publicly-traded organization, revenue per employee is $647,254, while income per employee is -$531,396. To continue investigating profitability, this company’s Return on Assets is posted at -15.83, Equity is -19.23, Total Capital is -17.73, and Invested Capital is -19.16. An extended look at the Principal structure reveals enduring liabilities to the total capital of 0.45 and enduring liabilities to assets of 0.40.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 372.01 points at the first support level, and at 367.27 for the second support level. However, for the 1st resistance point, the stock is sitting at 382.19, and for the 2nd resistance point, it is at 387.63.

argenx SE [ARGX] reported earnings per share of -$3.8 for its fiscal quarter that ended on 6/29/2022. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$4.83/share, meaning a difference of $1.03 and a surprise factor of 21.30%. By comparison, the stated earnings for the previous quarter ended on 3/30/2022 were -$4.36 per share as compared to estimates of -$4.87 per share, a difference of $0.51 representing a surprise of 10.50%.

Ratios To Look Out For

For context, argenx SE’s Current Ratio is 11.10. Also, the Quick Ratio is 8.08, while the Cash Ratio stands at 7.76. Considering the valuation of this stock, the price to sales ratio is 38.28, the price to book ratio is 7.31.